The Complete Response Letter stated that current data on midomafetamine capsules is insufficient for approval in treating patients with post-traumatic stress disorder.
FDA Issues Complete Response Letter to Lykos Therapeutics for Midomafetamine Capsules in the Treatment of Post-Traumatic Stress Disorder